Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

Exploiting Nanobodies’ Singular Traits

(2018) Jessica R. Ingram et al.   Annual Review of Immunology

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

(2018) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

(2018) Julius Strauss et al.   CLINICAL CANCER RESEARCH

Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins

(2018) Michael R. Turner et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

The promise and challenges of immune agonist antibody development in cancer

(2018) Patrick A. Mayes et al.   NATURE REVIEWS DRUG DISCOVERY

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

(2018) Michael R. Migden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Avelumab: A Review in Metastatic Merkel Cell Carcinoma

(2018) Matt Shirley   Targeted Oncology

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis

(2018) Shrujal Baxi et al.   BMJ-British Medical Journal

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis

(2018) Shrujal Baxi et al.   BMJ-British Medical Journal

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

(2018) Anders H. Kverneland et al.   OncoImmunology

Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia

(2018) Allison Barz Leahy et al.   Expert Review of Anticancer Therapy

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles

(2018) Ryan M Pearson et al.   Nanomedicine-Nanotechnology Biology and Medicine

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Deciphering the MHC-associated peptidome: a review of naturally processed ligand data

(2017) Kerrie Vaughan et al.   Expert Review of Proteomics

Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins

(2017) Lora Hamuro et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Immunogenicity assessment during the development of protein therapeutics

(2017) Amy S. Rosenberg et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Immunogenicity of Therapeutic Antibodies

(2017) Karien Bloem et al.   THERAPEUTIC DRUG MONITORING

Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia

(2017) Josep-Maria Ribera   Expert Review of Hematology

The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design

(2017) Ward Fleri et al.   Frontiers in Immunology

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics

(2017) Peter Bannas et al.   Frontiers in Immunology

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

(2017) Mariona Cabo et al.   OncoImmunology

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer

(2016) Brant A. Inman et al.   CLINICAL CANCER RESEARCH

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors

(2016) Shruti Agrawal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Driving CAR T-cells forward

(2016) Hollie J. Jackson et al.   Nature Reviews Clinical Oncology

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

(2016) Emilie M.J. van Brummelen et al.   ONCOLOGIST

Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective

(2015) Yow-Ming C. Wang et al.   AAPS Journal

Managing unwanted immunogenicity of biologicals

(2015) Maureen Deehan et al.   AUTOIMMUNITY REVIEWS

Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility

(2015) Meenu Wadhwa et al.   BIOLOGICALS

Immunogenicity assessment of monoclonal antibody products: A simulated case study correlating antibody induction with clinical outcomes

(2015) Ivana Knezevic et al.   BIOLOGICALS

Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody

(2015) L. Xue et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations

(2015) Kathryn Baksh et al.   SEMINARS IN ONCOLOGY

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

(2015) Luis H. Camacho   Cancer Medicine

A White Paper—Consensus and Recommendations of a Global Harmonization Team on Assessing the Impact of Immunogenicity on Pharmacokinetic Measurements

(2014) J. M. Sailstad et al.   AAPS Journal

Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality

(2014) M. Benjamin Hock et al.   AAPS Journal

Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations

(2014) G. Shankar et al.   AAPS Journal

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

(2014) C. Jackisch et al.   ANNALS OF ONCOLOGY

Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment

(2014) Ulrich H. Weidle et al.   SEMINARS IN ONCOLOGY

Antibody-Based Immunotherapy for Malignant Glioma

(2014) Patrick C. Gedeon et al.   SEMINARS IN ONCOLOGY

Immunogenicity of Subcutaneously Administered Therapeutic Proteins—a Mechanistic Perspective

(2013) Anas M. Fathallah et al.   AAPS Journal

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

(2013) Vibha Jawa et al.   CLINICAL IMMUNOLOGY

Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se

(2013) Yan Su et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors

(2011) Stephanie Delluc et al.   FASEB JOURNAL

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

(2011) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

(2010) Charlotte Krieckaert et al.   ARTHRITIS RESEARCH & THERAPY

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics☆

(2009) Satoshi Nagata et al.   ADVANCED DRUG DELIVERY REVIEWS

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

(2008) C. H. Chung   ONCOLOGIST